Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBr.small Co.2 Regulatory News (BSC)

Share Price Information for Br.small Co.2 (BSC)

Share Price is delayed by 15 minutes
Get Live Data
50.55    0.00 (0.00%)
Bid:
49.60
Ask:
51.50
Spread: 1.90 (3.831%)
Market Cap: £193.32m
BSC Live PriceLast checked at - London Stock Exchange

Intraday Br.small Co.2 Share Chart

Interim Management Statement to 30 September 2017

30 Nov 2017 13:28

RNS Number : 0121Y
British Smaller Companies VCT2 Plc
30 November 2017
 

 

British Smaller Companies VCT2 plc

Interim Management Statement

For the quarter ended 30 September 2017

British Smaller Companies VCT2 plc (the "Company") presents its interim management statement for the quarter ended 30 September 2017. The statement also includes relevant financial information between the end of the quarter and the date of this statement. A copy of this interim management statement can be found at www.bscfunds.com.

Overview

The Company has continued to make progress in the quarter with total return rising to 113.4 pence per ordinary share. This is an increase of 0.4 pence per ordinary share.

It is pleasing that improved profitability across a number of investments contributed to the £0.5 million increase in Net Asset Value ("NAV") in the period, prior to the payment of the interim dividend. The performances from GTK, Deep-Secure, Intelligent Office and Matillion in particular were strong contributors in the period. DisplayPlan has had a more difficult trading period, albeit it is very well funded to be able to cope with the challenges and whilst the additional investment in the sales channel by Business Collaborator is slower to come through than anticipated the business remains confident in being able to deliver on its medium-term growth plans.

Performance

 

30 September 2017

Movement

30 June 2017

Net Assets (£m)

58.6

(0.8)

59.4

NAV per share (PPS)

57.9p

(1.1p)

59.0p

Cumulative dividends paid (PPS)

55.5p

1.5p

54.0p

Total Return (PPS)

113.4p

0.4p

113.0p

Shares in issue

101,091,180

456,434

100,634,746

 

The total return at 30 September 2017, calculated by reference to the NAV per ordinary share and the cumulative dividends paid per ordinary share, was 113.4 pence per ordinary share compared to 113.0 pence per ordinary share at 30 June 2017. Cumulative dividends paid were up 1.5 pence per ordinary share at 55.5 pence per ordinary share (30 June 2017: 54.0 pence per ordinary share).

 

The unaudited NAV per ordinary share as at 30 September 2017 was 57.9 pence per ordinary share (30 June 2017: 59.0 pence per ordinary share) representing a decrease of 1.1 pence per ordinary share. The decrease in NAV per ordinary share is primarily due to the interim dividend of 1.5 pence per ordinary share for the year ending 31 December 2017, offset by the net upward movement in the overall portfolio valuation.

Dividends and shares in issue

On 27 September 2017 the Company purchased 150,000 ordinary shares of 10 pence each at a price of 55.13 pence per ordinary share. These shares were placed in treasury.

Pursuant to its dividend re-investment scheme on 29 September 2017 the Company issued 606,434 ordinary shares at a price of 54.63 pence per ordinary share.

The number of ordinary shares in issue at 30 September 2017 was 101,091,180 (30 June 2017: 100,634,746). In addition, at 30 September 2017 the Company held 3,405,746 ordinary shares in treasury (30 June 2017: 3,255,746).

Subsequent to the quarter end on 20 October 2017 the Company purchased 290,605 ordinary shares of 10 pence each at a price of 55.13 pence per ordinary share. These shares were placed in treasury.

 Net assets

Net assets at 30 September 2017 comprised the following:

 

£000

% of net assets

Unquoted investments at fair value

38,392

65.6

Quoted investments at bid price

2,073

3.5

Total investments

40,465

69.1

Cash and cash equivalents

16,948

28.9

Other net current assets

1,158

2.0

Net assets

58,571

100.0

 

The investment portfolio at 30 September 2017 was comprised as follows:

 

Valuation

£000

Valuation as a % of net assets

ACC Aviation

3,704

6.3

Intelligent Office

3,264

5.6

Mangar Health Limited

2,654

4.5

KeTech Enterprises Limited

2,123

3.6

Springboard Research Holdings Limited

1,922

3.3

GTK (Holdco) Limited

1,790

3.1

Gill Marine Holdings Limited

1,761

3.0

Business Collaborator Limited

1,650

2.8

Immunobiology Limited

1,612

2.8

Matillion Limited

1,569

2.7

 

22,049

37.7

Other investments

18,416

31.4

Total investments

40,465

69.1

During the quarter to 30 September 2017 the Company made two new investments of £1.2 million into Friska Limited, a Bristol based chain of restaurants and £0.6 million into e2E Engineering Limited, a leading technical consultancy operating in the telecommunications market with particular expertise in satellite communications.

In the quarter to 30 September 2017 the realisation and repayment of investments generated cash proceeds of £0.6 million, including £0.2 million from the realisation of the Company's final interest in Harvey Jones. This takes the total return on this investment to £2.2 million, a multiple of 1.4x cost.

Portfolio Performance

Over the quarter to 30 September 2017 aggregate unrealised portfolio valuations have increased by £0.5 million.

The Board continues to follow its policy of maintaining a diversified portfolio. At 30 September 2017, only two investments represented more than 5 per cent of the Company's NAV.

Recent budget

It was pleasing that the Government reaffirmed its commitment to the Venture Capital Trust Schemes as one of the tools to support investment in the UK's small businesses which remain an engine of future growth and innovation. The changes announced seek to focus investment on earlier stage higher risk businesses and away from any capital preservation/asset-backed investments and also to achieve higher levels of investment in qualifying companies.

A new "risk-based principles" test is to be introduced to help achieve the focussing of investments, with guidelines expected to be published on 1 December 2017. Whilst the test will not formally be brought into law until the Finance Bill is given Royal Assent, it is believed that the advance assurance will operate from 1 December 2017 as if the new test applied. Your Board and Investment Adviser welcome the new test and do not believe that its introduction will have a material impact on the Company's operations or investment policy.

There are two new qualifying investment tests; the first is that for the Company as a whole 80 per cent of its investments will have to be held in Qualifying Investments as opposed to the current test of 70 per cent; for the Company this comes into force from 1 January 2020. The second test applies to financial years commencing on or after 6 April 2019 where 30 per cent of any new funds raised have to be invested in Qualifying Investments within 12 months. This will apply for the year ending 31 December 2020. It is not believed that either of these changes will significantly impact the Company.

Outlook

Although we remain in uncertain times and it is unclear what the full implications of the UK's decision to leave the European Union will mean for many businesses, your Board is confident that the businesses in your Company's portfolio should be able to adapt to the new economic environment and the pipeline of new investments is continuing to develop.

The Company is pleased to note the increased level of investment opportunities and, as last year, will be seeking to raise up to €5 million by way of a non-prospectus top-up that it plans to launch on 11 January 2018.

Your Board will continue to seek to grow and diversify the portfolio, recognising that due to the regulatory environment, its composition will change over time as the current portfolio is realised and replaced with growth capital investments in earlier stage, younger businesses. While the current portfolio should continue to generate more consistent returns, in the medium to long term there is likely to be a greater volatility of returns and your Board will continue to monitor its dividend and buy-back policies through this transition.

Your Board remains committed to continuing to build a strong and diversified portfolio to deliver long-term value to shareholders.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU No. 596/2014). Upon the publication of this announcement via Regulatory Information Service this inside information is now considered to be in the public domain.

 

30 November 2017

 

For further information please contact:

David Hall YFM Private Equity Limited Tel: 0113 244 1000

Jonathan Becher Panmure Gordon (UK) Limited Tel: 0207 886 2715

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTWGGCPGUPMGWU
Date   Source Headline
6th May 20267:00 amRNSDividend Declaration
20th Apr 202610:01 amRNSAdmission to Trading
1st Apr 20269:00 amRNSIssue of Equity
27th Mar 20264:12 pmRNSTransaction in Own Shares
23rd Mar 202610:45 amRNSPublication of a Supplementary Prospectus
19th Mar 20267:00 amRNSAnnual Financial Report
30th Jan 20267:00 amRNSAdmission of Further Securities to Trading
7th Jan 20269:31 amRNSDirector/PDMR Shareholding
7th Jan 20269:30 amRNSIssue of Equity
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
23rd Dec 20258:54 amRNSAmendments to AIFM Agreements
22nd Dec 20259:13 amRNSTransaction in Own Shares
22nd Dec 20259:13 amRNSTransaction in Own Shares
18th Dec 202512:14 pmRNSClose of Offers to new Applications
18th Dec 202512:14 pmRNSClose of Offers to new Applications
28th Nov 202510:00 amRNSInterim Management Statement
20th Nov 20259:00 amRNSOffer Update
31st Oct 202510:01 amRNSPayment of dividend and issue of Equity
10th Oct 20253:41 pmRNSOffer Update
2nd Oct 20259:00 amRNSOffer Update
25th Sep 20259:04 amRNSPublication of a Prospectus
23rd Sep 20257:00 amRNSTransaction in Own Shares
12th Sep 20257:00 amRNSHalf-year Report
22nd Aug 202510:45 amRNSNew combined offer for subscription
24th Jun 20257:00 amRNSTransaction in Own Shares
23rd Jun 202510:20 amRNSPayment of Dividend and Issue of Equity
13th Jun 20251:30 pmRNSInterim Management Statement
12th Jun 202510:46 amRNSResult of AGM
13th May 202512:54 pmRNSDividend Declaration
1st Apr 20258:02 amRNSDirector/PDMR Shareholding
1st Apr 20258:00 amRNSIssue of Equity
26th Mar 20255:15 pmRNSTransaction in Own Shares
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
24th Mar 202512:45 pmRNSPublication of Supplementary Prospectus
18th Mar 20251:00 pmRNSAnnual Financial Report
30th Jan 20259:05 amRNSDirector/PDMR Shareholding
30th Jan 20259:00 amRNSIssue of Equity
27th Jan 20259:21 amRNSPayment of dividend and issue of shares
8th Jan 20252:14 pmRNSClose of Offer to new Applications
8th Jan 20252:13 pmRNSClose of Offer to new Applications
17th Dec 20242:13 pmRNSNominal Capital Reduction
17th Dec 20247:00 amRNSDividend Declaration
16th Dec 20245:08 pmRNSTransaction in Own Shares
29th Nov 20249:00 amRNS3rd Quarter Results
20th Nov 20241:00 pmRNSOffer Update
20th Nov 20241:00 pmRNSOffer Update
12th Nov 20241:52 pmRNSResult of General Meeting
1st Nov 202411:04 amRNSPayment of Dividend and Allotment of Shares
1st Nov 20247:00 amRNSOffer Update
1st Nov 20247:00 amRNSOffer Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.